FGEN
FibroGen Inc
Company Overview
| Mkt Cap | $34.79M | Price | $8.42 |
| Volume | 30.78K | Change | +1.45% |
| P/E Ratio | -0.7 | Open | $8.31 |
| Revenue | $29.6M | Prev Close | $8.30 |
| Net Income | $-47.6M | 52W Range | $4.85 - $21.95 |
| Div Yield | N/A | Target | $43.00 |
| Overall | 28 | Value | 40 |
| Quality | -- | Technical | 16 |
No chart data available
About FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Latest News
FGEN Evaluates Impact of UK Renewable Scheme Changes
Analysts Are Bullish on Top Healthcare Stocks: Akebia Therapeutics (AKBA), FibroGen (FGEN)
FibroGen Receives $6.4 Million Payment from AstraZeneca
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FGEN | $8.42 | +1.4% | 30.78K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |